Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine

Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine

IntroductionCurrently, there are no FDA-approved medications to treat methamphetamine addiction, including the inflammatory, neurotoxic, and adverse neuropsychiatric effects. We have shown that partial (p)MHC class II constructs (i.e., Recombinant T-cell receptor Ligand – RTL1000), comprised of the...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Jennifer M. Loftis, Sankrith Ramani, Evan J. Firsick, Rebekah Hudson, Anh Le-Cook, Kevin S. Murnane, Arthur Vandenbark, Renee L. Shirley
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Frontiers Media S.A. 2023-11-01
Sarja:Frontiers in Psychiatry
Aiheet:
addiction
chemokine
drug discovery
frontal cortex
inflammation
methamphetamine
Linkit:https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1259041/full

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1259041/full

Samankaltaisia teoksia